Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 13/20 | 0.61 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17733777 | 1.00 | CXCR4 (0.61) | CXCR4CXCL12KDM4ERAD52HRH4 | |
| Hydrochloric Acid SCHEMBL9714202 | 0.97 | CXCR4 (0.59) | CXCR4CXCL12KDM4ERAD52HRH4 | |
| SCHEMBL11523136 | 0.97 | CXCR4 (0.57) | CXCR4CXCL12KDM4ERAD52HRH4 | |
| SCHEMBL10939737 | 0.92 | CXCR4 (0.66) | CXCR4CXCL12KDM4ERAD52HRH4 | |
| SCHEMBL4739261 | 0.92 | CXCR4 (0.53) | CXCR4CXCL12KDM4ERAD52HRH4 | |
| SCHEMBL4786617 | 0.92 | CXCR4 (0.53) | CXCR4CXCL12KDM4ERAD52HRH4 | |
| SCHEMBL10604006 | 0.92 | CXCR4 (0.53) | CXCR4CXCL12KDM4ERAD52HRH4 | |
| SCHEMBL4786588 | 0.92 | CXCR4 (0.53) | CXCR4CXCL12KDM4ERAD52HRH4 | |
| SCHEMBL841438 | 0.92 | CXCR4 (0.53) | CXCR4CXCL12KDM4ERAD52HRH4 | |
| SCHEMBL4740704 | 0.91 | CXCR4 (0.52) | CXCR4CXCL12KDM4EHRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5145874-A | Phospholipase inhibitor, hypoglycemic agent, antidiabetic, obesity | THE UPJOHN COMPANY (US) | 1992-09-08 | — | — | US | claimed |
| EP-0243449-A1 | CYCLIC HYDROCARBONS WITH AN AMINOALKYL SIDECHAIN | THE UPJOHN COMPANY (US) | 1987-11-04 | — | — | EP | claimed |
| WO-1987002367-A2 | CYCLIC HYDROCARBONS WITH AN AMINOALKYL SIDECHAIN | THE UPJOHN COMPANY (US) | 1987-04-23 | — | — | WO | claimed |
| US-5373095-A | Steroid compounds | THE UPJOHN COMPANY (US) | 1994-12-13 | — | — | US | disclosed |
| US-5334712-A | Estrane or androstane pyridinyl alkyl or alkylphenyl amine steroids for antidiabetes and obesity | THE UPJOHN COMPANY (US) | 1994-08-02 | — | — | US | disclosed |
| US-5274089-A | A estra-1,3,5(10)-triene derivative | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
| US-5196542-A | Phospholipase A2 inhibitors | THE UPJOHN COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| US-5187299-A | Phospholipase inhibitors; treating diabetes, obesity | THE UPJOHN COMPANY (US) | 1993-02-16 | — | — | US | disclosed |
| US-5145874-A | Phospholipase inhibitor, hypoglycemic agent, antidiabetic, obesity | THE UPJOHN COMPANY (US) | 1992-09-08 | — | — | US | disclosed |
| US-4917826-A | TREATING DIABETES AND OBESITY | THE UPJOHN COMPANY (US) | 1990-04-17 | — | — | US | disclosed |